Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q4 EPS by 8c
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $250.68 +2.51%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
RIBT, INLB, FTXP, More
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
RIBT, INLB, FTXP, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q4 EPS of $1.17, $0.08 better than the analyst estimate of $1.09. Revenue for the quarter came in at $83.5 million versus the consensus estimate of $80.84 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals, Inc. (JAZZ) click here.
For earnings history and earnings-related data on Jazz Pharmaceuticals, Inc. (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- KeyBanc on National Fuel Gas (NFG): 'P&S Growth an Underappreciated Hedge to Weak Natural Gas Prices'
- Piper Sandler: 'Amazon.com (AMZN) AMZN Looks Best Positioned'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
